EA202090401A1 - Анти-tim-3 антитела и их применение - Google Patents
Анти-tim-3 антитела и их применениеInfo
- Publication number
- EA202090401A1 EA202090401A1 EA202090401A EA202090401A EA202090401A1 EA 202090401 A1 EA202090401 A1 EA 202090401A1 EA 202090401 A EA202090401 A EA 202090401A EA 202090401 A EA202090401 A EA 202090401A EA 202090401 A1 EA202090401 A1 EA 202090401A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- tim
- application
- diseases
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538277P | 2017-07-28 | 2017-07-28 | |
| PCT/US2018/043800 WO2019023410A1 (en) | 2017-07-28 | 2018-07-26 | ANTI-TIM-1 ANTIBODIES AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202090401A1 true EA202090401A1 (ru) | 2020-05-18 |
Family
ID=65040974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090401A EA202090401A1 (ru) | 2017-07-28 | 2018-07-26 | Анти-tim-3 антитела и их применение |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11214615B2 (enExample) |
| EP (2) | EP4039274A1 (enExample) |
| JP (1) | JP2021500916A (enExample) |
| KR (1) | KR20200032156A (enExample) |
| CN (1) | CN111050797B (enExample) |
| AU (1) | AU2018306321A1 (enExample) |
| CA (1) | CA3070295A1 (enExample) |
| EA (1) | EA202090401A1 (enExample) |
| WO (1) | WO2019023410A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12454574B2 (en) | 2018-10-30 | 2025-10-28 | Board Of Regents, The University Of Texas System | Anti-CD79B antibodies and chimeric antigen receptors and methods of use thereof |
| WO2021051352A1 (zh) * | 2019-09-19 | 2021-03-25 | 上药生物治疗（香港）有限公司 | 一种分离的抗原结合蛋白及其用途 |
| JP7900284B2 (ja) * | 2019-12-17 | 2026-08-04 | フェインズ セラピューティクス，インコーポレーテッド | 鎖間システインが選択的にマッチングされた二重特異性抗体及びその使用 |
| EP4084826A2 (en) * | 2019-12-30 | 2022-11-09 | University Of Louisville Research Foundation, Inc. | Virus-like particle binding agents, related compositions, and related methods |
| WO2021169948A1 (zh) * | 2020-02-24 | 2021-09-02 | 苏州恒康生命科学有限公司 | Tim3结合分子及其应用 |
| US20230183371A1 (en) * | 2020-04-30 | 2023-06-15 | Board Of Regents, The University Of Texas System | Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof |
| GB202015115D0 (en) * | 2020-09-24 | 2020-11-11 | Imperial College Innovations Ltd | ZIP12 Antibody |
| CN113151186B (zh) * | 2021-02-04 | 2022-02-18 | 上海交通大学 | 抗人cd271的单克隆抗体及用途 |
| CN117377692A (zh) | 2021-04-23 | 2024-01-09 | 苏州逻晟生物医药有限公司 | Tim-3-靶向抗体及其用途 |
| WO2023105528A1 (en) * | 2021-12-12 | 2023-06-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to ceacam1 |
| CN116925216B (zh) * | 2022-04-11 | 2024-09-24 | 东莞市朋志生物科技有限公司 | 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒 |
| WO2025035133A1 (en) * | 2023-08-10 | 2025-02-13 | Board Of Regents, The University Of Texas System | Bmp-7 antibody compositions & methods for treating cancer |
| CN119264251B (zh) * | 2024-12-09 | 2025-03-14 | 上海交通大学医学院附属仁济医院 | 一种cbln1单克隆抗体和应用 |
| CN120590523B (zh) * | 2025-06-20 | 2026-01-27 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 一种犬瘟热病毒n蛋白单克隆抗体，快速检测胶体金试纸条及其制备方法 |
| CN120623323B (zh) * | 2025-06-23 | 2026-04-21 | 江苏东抗生物医药科技有限公司 | 一种靶向猴痘病毒的抗体及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4694128B2 (ja) | 2002-01-30 | 2011-06-08 | ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド | ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法 |
| AU2005256113B2 (en) | 2004-07-09 | 2011-02-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
| KR20070094890A (ko) * | 2004-10-25 | 2007-09-27 | 머크 앤드 캄파니 인코포레이티드 | 안티 ａｄｄｌ 항체 및 그 용도 |
| US9416165B2 (en) | 2007-10-26 | 2016-08-16 | The Regents Of The University Of California | Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors |
| US8647623B2 (en) | 2009-04-10 | 2014-02-11 | Kyowa Hakko Kirin Co., Ltd | Method for treatment of blood tumor using anti-TIM-3 antibody |
| CN103079644B (zh) * | 2010-06-11 | 2017-02-15 | 协和发酵麒麟株式会社 | 抗tim‑3抗体 |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| CN103173412B (zh) * | 2012-12-07 | 2015-04-22 | 天津三箭生物技术有限公司 | 小鼠抗人cd20单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
| KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
| CA2913052A1 (en) * | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| PL3099717T3 (pl) * | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| AU2015340056A1 (en) | 2014-10-27 | 2017-05-25 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| MY193661A (en) | 2014-11-06 | 2022-10-24 | Hoffmann La Roche | Anti-tim3 antibodies and methods of use |
| US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| AU2016229189A1 (en) | 2015-03-06 | 2017-09-21 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind TIM3 |
| PL3277321T3 (pl) | 2015-04-01 | 2024-11-18 | Anaptysbio, Inc. | Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3) |
| US20180271861A1 (en) | 2015-07-14 | 2018-09-27 | Kyowa Hakko Kirin Co., Ltd. | Therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody |
| US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| EP3337826A1 (en) | 2015-08-20 | 2018-06-27 | Sutro Biopharma, Inc. | Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies |
| WO2017055393A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules |
| MA43028B1 (fr) | 2015-10-02 | 2021-09-30 | Hoffmann La Roche | Anticorps bispécifiques pour pd1 et tim3 |
| PT3370768T (pt) | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| EP3448874A4 (en) * | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
-
2018
- 2018-07-26 JP JP2020527848A patent/JP2021500916A/ja not_active Ceased
- 2018-07-26 US US16/633,262 patent/US11214615B2/en active Active
- 2018-07-26 CN CN201880050603.9A patent/CN111050797B/zh active Active
- 2018-07-26 KR KR1020207004818A patent/KR20200032156A/ko not_active Withdrawn
- 2018-07-26 CA CA3070295A patent/CA3070295A1/en active Pending
- 2018-07-26 EA EA202090401A patent/EA202090401A1/ru unknown
- 2018-07-26 WO PCT/US2018/043800 patent/WO2019023410A1/en not_active Ceased
- 2018-07-26 EP EP22151361.7A patent/EP4039274A1/en not_active Withdrawn
- 2018-07-26 EP EP18837224.7A patent/EP3658185A4/en not_active Withdrawn
- 2018-07-26 AU AU2018306321A patent/AU2018306321A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021500916A (ja) | 2021-01-14 |
| EP3658185A1 (en) | 2020-06-03 |
| CN111050797B (zh) | 2024-04-30 |
| CA3070295A1 (en) | 2019-01-31 |
| KR20200032156A (ko) | 2020-03-25 |
| WO2019023410A1 (en) | 2019-01-31 |
| US11214615B2 (en) | 2022-01-04 |
| CN111050797A (zh) | 2020-04-21 |
| US20210032330A1 (en) | 2021-02-04 |
| EP4039274A1 (en) | 2022-08-10 |
| AU2018306321A1 (en) | 2020-02-13 |
| EP3658185A4 (en) | 2021-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004730B (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
| ZA202000373B (en) | Anti-cd47 antibodies and uses thereof | |
| MX2024015440A (es) | Anticuerpos anti-phf-tau y usos de estos | |
| CY1122265T1 (el) | Αντισωματα εναντι ταυ και χρησεις αυτων | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| HK1255604A1 (zh) | 抗pd-l1抗体及其用途 | |
| MX2022014914A (es) | Compuestos de interaccion con glicanos y metodos de uso. | |
| HK1254880A1 (zh) | 抗pd-1抗体及其应用 | |
| HK1255331A1 (zh) | 抗pcsk9抗体及其应用 | |
| PH12018500578A1 (en) | Methods of treating inflammatory diseases | |
| EA202191380A1 (ru) | Антитела к альфа-синуклеину и их применение | |
| EA201691541A1 (ru) | Новые анти-baff антитела | |
| MY200162A (en) | Anti-gitr antibodies and uses thereof | |
| PH12017502020A1 (en) | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor | |
| EA202190807A1 (ru) | Антитела к синуклеину | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
| EA201790336A1 (ru) | Антитела к ангиопоэтинподобному белку 4 и способы применения | |
| EA202092122A1 (ru) | Антитела против tip-1 и их применения | |
| EA202092123A1 (ru) | Антитела против клаудина 18.2 и их применения | |
| EA202192254A1 (ru) | Fcmr-связывающие молекулы и их применение | |
| EA201990493A1 (ru) | Антитела к гм-ксф и их применения | |
| EA202092121A1 (ru) | Антитела против cd73 и их применения | |
| EA201991851A1 (ru) | Антитела против sirp-альфа |